XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look first for durable economics and a margin of safety. XOMA is a royalty aggregator: it buys rights to future milestone and royalty payments on biotech products and clinical assets, with only 14 employees. That can be a capital-light niche, but the moat is not obvious; results depend on partners' trials, approvals, and sales. In the first quarter of 2026, revenue was just $310,000 while net income was $4.5 million, an unusual spread that suggests lumpy, non-recurring items. Trailing free cash flow was negative $13.9 million, and D/E is 1.10. ROE is 34.23%, but ROCE is only 1.28%, so the high ROE may reflect leverage or accounting rather than strong operating returns. The data show revenue growth of -92.82% and profit growth of 88.64%, showing how erratic reported figures can be. FairStock's calculations at the 2026-07-21 close of $24.98 show a P/E of 24.98, P/B of 3.21, Graham Number of $14.60, and a margin of safety of -71.10%. The 8.63% dividend yield on the cumulative preferred is attractive, and the beta of 0.86 is modest, but a perpetual preferred depends on the company's ability to generate cash. FairStock Score is 52/100 and Piotroski is 5/9. The Lynch category is none because only 0 years of filed results are available, below the required 3. I see a speculative income instrument, not a Graham bargain; the price looks full relative to book and Graham value, and cash flow needs monitoring.

In plain English: XOMA Royalty buys rights to future payments from biotech drugs and milestones. The business is tiny, with 14 employees, and its results are uneven: in the first quarter of 2026 it had $310,000 of revenue and $4.5 million of net income, while over the past year it used more cash than it generated. At $24.98, the preferred stock offers an 8.63% dividend and sits near its 52-week low, but the price looks high compared with the company's accounting value. Overall, this looks like a higher-risk income security rather than a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-21 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer